Health Matters

Tag: generics

  • Generic Semaglutide Pricing Could Disrupt Global Markets

    New research reveals that manufacturers could sell generic versions of Novo Nordisk’s blockbuster drugs, Ozempic and Wegovy, for less than $3 a month. This study highlights a massive gap between current list prices and actual production costs. It suggests a future where powerful weight-loss treatments are accessible to billions. The Massive Gap In Generic Semaglutide Pricing Researchers at the University…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Competition Commission Pharma Probe Expands Scope

    The Competition Commission has initiated an early-stage investigation into several pharmaceutical manufacturers following a complaint from the national health department. The companies named include Ascendis, Pharma Q and Sonke, all of which supply medicines to the state. Competition Commission spokesperson Siyabulela Makunga confirmed that a probe is underway. He would not elaborate on the allegations, saying only that the investigation…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Barrs Pharmaceuticals Secures R92m Hetero Investment

    Barrs Pharmaceuticals has exited business rescue after agreeing to sell a controlling stake to Hetero. The deal signals a reset for a local manufacturer that has faced both operational disruption and regulatory pressure. Business rescue consultant Karl Gribnitz announced that the Indian generics group’s South African subsidiary will acquire 78% of Barrs for R92m. The group intends this investment to…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Generic Semaglutide Set to Disrupt Global GLP‑1 Market

    Aspen Pharmacare is gearing up to launch one of the world’s first generic semaglutide in Canada, capitalising on the recent loss of patent protection for Novo Nordisk’s blockbuster GLP‑1 weight‑loss injection. The move could be a pivotal moment for access and competition in an increasingly lucrative market. Canada’s early patent expiry of semaglutide has drawn global attention. Industry leaders see…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in